12 Best Medical Stocks To Buy Under $20

Page 10 of 11

2. Roivant Sciences Ltd. (NASDAQ:ROIV)

Share Price as of January 8: $11.02

Number of Hedge Fund Holders: 50

Roivant Sciences Ltd. (NASDAQ:ROIV) is an American multinational healthcare company that focuses on improving drug development through innovative technology. The company operates a unique model where it creates subsidiaries, known as “Vants,” to develop and commercialize a variety of solutions. With an aim to improve patient outcomes by accelerating the delivery of effective medicines, ROIV ranks among the best medical stocks to buy.

Tourlite Capital Management, an investment management firm, has a positive outlook on Roivant Sciences Ltd. (NASDAQ:ROIV). Tourlite Capital likes the stock because of the company’s pipeline programs that have seen positive developments recently. In its third-quarter 2024 investor letter, the management firm expressed confidence that progress on programs like mosliciguat and IMVT-1402 could reveal the true potential of Roivant Sciences Ltd.’s (NASDAQ:ROIV) platform.

The company has an impressive pipeline, featuring a range of advanced treatments. Notably, IMVT-1402, a monoclonal antibody targeting autoimmune diseases, has cleared five Investigational New Drug (IND) applications and is on track to start a pivotal trial for difficult-to-treat rheumatoid arthritis by March 31, 2025.

Another key program is mosliciguat, which Roivant Sciences Ltd. (NASDAQ:ROIV) introduced in September 2024. Mosliciguat is an innovative inhaled medication designed for once-daily use and acts as a soluble guanylate cyclase (sGC) activator to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Around 200,000 patients in the US and Europe are affected by this condition, which currently has limited or no effective treatment options.

Page 10 of 11